Matches in Nanopublications for { ?s ?p "There are no FDA or manufacturer guidelines for use of clozapine in pediatric population. Clozapine has been used in the treatment of refractory schizophrenia in child and adolescents. It is estimated that 40%–50% of patients with very early-onset schizophrenia (VEOS) are nonresponders to first-line neuroleptics and that clozapine is likely to be beneficial." ?g. }
Showing items 1 to 2 of
2
with 100 items per page.
- association label "There are no FDA or manufacturer guidelines for use of clozapine in pediatric population. Clozapine has been used in the treatment of refractory schizophrenia in child and adolescents. It is estimated that 40%–50% of patients with very early-onset schizophrenia (VEOS) are nonresponders to first-line neuroleptics and that clozapine is likely to be beneficial." assertion.
- association label "There are no FDA or manufacturer guidelines for use of clozapine in pediatric population. Clozapine has been used in the treatment of refractory schizophrenia in child and adolescents. It is estimated that 40%–50% of patients with very early-onset schizophrenia (VEOS) are nonresponders to first-line neuroleptics and that clozapine is likely to be beneficial." assertion.